New combo therapy tested to stop aggressive skin Cancer's comeback
NCT ID NCT07400302
Summary
This study is for people with a rare and aggressive type of skin cancer called mucosal melanoma who have had it surgically removed. It is testing if adding a drug called sintilimab to standard chemotherapy is better at preventing the cancer from coming back than chemotherapy alone. The trial will enroll 220 adults whose cancer tests positive for a specific marker (PD-L1) to see which treatment is more effective and safer.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PD-L1 POSITIVE are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
The first hospital of Jilin University
RECRUITINGChangchun, Jilin, 130000, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.